Shorter Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

To the Editor: Gillespie et al. (Oct. 23 issue) 1 report that two moxifloxacin-containing regimens for the treatment of tuberculosis were not effective with a shortened treatment period of 4 months. The authors used a moxifloxacin dose of 400 mg per day, which may have contributed to the unfavorable results. Rifampin decreases the average exposure to moxifloxacin (assessed according to the area under the curve [AUC]) by approximately 30%, 2 which can be compensated for by an increase in the dose of moxifloxacin. 3 In addition, preclinical data combined with pharmacokinetic and pharmacodynamic modeling showed that a higher moxifloxacin dose, of 800 mg . . .